Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which blood thinner is safest for ICU patients with kidney failure? large study aims to find out

NCT ID NCT07365644

Knowledge-focused Sponsor: Centre Hospitalier le Mans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at ICU patients with kidney failure who need blood thinners to prevent dangerous clots. Doctors currently use different types of heparin, but it's unclear which is safest and works best when kidneys are weak. The study will track over 1,100 patients to compare bleeding risks and clot prevention across the various heparin options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,111 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with impaired renal function in intensive care

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of impaired renal function (one of the two criteria must be met, both criteria may be met): Glomerular filtration rate (GFR) \<30ml/min/1.7m² according to the MDRD or CKD-EPI formula. Acute renal failure (observed or presumed increase in creatinine in the last 7 days) KDIGO stage 3 (creatinine ≥3 times baseline creatinine or ≥354 µmol/L (4 mg/dL) or urine output \<0.3 mL/kg/h for ≥24 hours or initiation of extrarenal clearance or anuria for ≥12 hours) \- Expected length of stay in intensive care ≥48 hours Exclusion Criteria: * Age ≤ 18 years * Long-term dialysis patient * Current or recent hemorrhage during this hospitalization * Patient receiving curative anticoagulation or treated long-term prior to admission with curative anticoagulation. * Thrombosis present on admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prophylactic anticoagulation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prophylactic anticoagulation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHR Metz-Thionville Hôpital Bel-Air

    Thionville, 57100, France

  • CHR Metz-Thionville site Mercy

    Metz, 57000, France

  • CHRU Nancy

    Nancy, 54511, France

  • CHU Angers

    Angers, 49000, France

  • CHU Brest

    Brest, 29609, France

  • CHU Caen

    Caen, 14000, France

  • CHU Nantes

    Nantes, 44000, France

  • CHU Orléans

    Orléans, 45100, France

  • CHU Poitiers

    Poitiers, 86000, France

  • CHU Rennes

    Rennes, 35000, France

  • CHU Tours

    Tours, 37000, France

  • CHU bordeaux

    Bordeaux, 33000, France

  • Centre Hospitalier Le Mans

    Le Mans, 72000, France

  • Centre Hospitalier de Saint-Nazaire

    Saint-Nazaire, 44600, France

  • Groupe Hospitalier Bretagne Sud

    Lorient, 56322, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.